Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 11/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90849 | 0.88 | BRD4 (0.37) | BRD4IDH2CCNT1CDK9ALDH1A1 | |
| SCHEMBL8576076 | 0.74 | USP30 (0.33) | ALDH1A1LMNAHPGD | |
| SCHEMBL90961 | 0.71 | GRIA2 (0.42) | GRIA2CYP2C19CCNT1CDK9 | |
| SCHEMBL8545306 | 0.70 | ESR1 (0.36) | BRD4CCNT1CDK9ALDH1A1LMNA | |
| SCHEMBL8547161 | 0.68 | IKBKB (0.44) | CCNT1CDK9 | |
| SCHEMBL8528196 | 0.67 | GRIA2 (0.42) | GRIA2CYP2C19 | |
| SCHEMBL11936359 | 0.66 | CNR2 (0.50) | GRIA2IDH2SMN1; SMN2 | |
| SCHEMBL90919 | 0.66 | BRD4 (0.34) | BRD4ALDH1A1HPGDSMN1; SMN2LRRK2 | |
| SCHEMBL90996 | 0.66 | GRIA2 (0.43) | GRIA2CYP2C19CCNT1CDK9 | |
| SCHEMBL11936355 | 0.64 | CNR2 (0.48) | GRIA2IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | BRD4 482/4885GRIA2 634/4885CYP2C19 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.